The FDA approved lisocabtagene maraleucel for treatment of adults with relapsed or refractory large B-cell lymphoma after one prior therapy.
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045
FDA expands Breyanzi approval for relapsed or refractory large B-cell lymphoma
Default sub title
minute read
by Healio | June 27, 2022
